Partners & Customers
8About 4D Pharma
4D Pharma (NASDAQ: LBPS) researches and develops pharmaceutical products in new live biotherapeutic areas in the United Kingdom. The Company's first-generation programs include Blautix, a treatment for irritable bowel syndrome; Thetanix, a treatment for pediatric Crohns; and Rosburix, a treatment for pediatric ulcerative colitis.
Want to inform investors similar to 4D Pharma about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Research containing 4D Pharma
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned 4D Pharma in 10 CB Insights research briefs, most recently on Dec 16, 2022.
Latest 4D Pharma News
Jan 29, 2023
Results that will be out on January 30 include Larsen & Toubro, Bajaj Finserv, Tech Mahindra, Bharat Petroleum Corporation, Bajaj Holdings & Investment, GAIL, SRF, Punjab National Bank, REC, Laurus Labs, IIFL Finance, Trident, Exide Industries, Nippon Life India Asset Management, Mazagon Dock Shipbuilders, Welspun as well as Inox Leisure.
4D Pharma Acquisitions
2 Acquisitions
4D Pharma acquired 2 companies. Their latest acquisition was Biomar on April 08, 2016.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
4/8/2016 | Acquired | 3 | ||||
2/15/2016 |
Date | 4/8/2016 | 2/15/2016 |
|---|---|---|
Investment Stage | ||
Companies | ||
Valuation | ||
Total Funding | ||
Note | Acquired | |
Sources | 3 |
4D Pharma Partners & Customers
8 Partners and customers
4D Pharma has 8 strategic partners and customers. 4D Pharma recently partnered with Columbia Care on October 10, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
10/21/2021 | Partner | United States | Cannabis capsules on prescription: Simplifying medical cannabis for patients and doctors - Grow The capsules are manufactured under the highest standards , by Columbia Care 's UK partner , IPS Pharma -- a leading pharmaceutical manufacturer that is licensed by the UK 's Medicines and Healthcare products Regulatory Agency and distributed by Columbia Care 's UK market access partner , Grow Pharma Ltd. . | 1 | |
8/25/2021 | Partner | ||||
7/27/2021 | Vendor | ||||
6/15/2021 | Partner | ||||
10/10/2019 | Partner |
Date | 10/21/2021 | 8/25/2021 | 7/27/2021 | 6/15/2021 | 10/10/2019 |
|---|---|---|---|---|---|
Type | Partner | Partner | Vendor | Partner | Partner |
Business Partner | |||||
Country | United States | ||||
News Snippet | Cannabis capsules on prescription: Simplifying medical cannabis for patients and doctors - Grow The capsules are manufactured under the highest standards , by Columbia Care 's UK partner , IPS Pharma -- a leading pharmaceutical manufacturer that is licensed by the UK 's Medicines and Healthcare products Regulatory Agency and distributed by Columbia Care 's UK market access partner , Grow Pharma Ltd. . | ||||
Sources | 1 |
4D Pharma Team
1 Team Member
4D Pharma has 1 team member, including former Chief Medical Officer, John Weinberg.
Name | Work History | Title | Status |
|---|---|---|---|
John Weinberg | Chief Medical Officer | Former |
Name | John Weinberg |
|---|---|
Work History | |
Title | Chief Medical Officer |
Status | Former |
Compare 4D Pharma to Competitors
SciBac aims to target Clostridium difficile (C. diff), a potentially fatal and often recurring gastrointestinal infection. Using "Evolutionary" live biotherapeutics, it stops colonization, neutralizes toxins, and directly kills C. diff organisms. The company is also developing a single-strain inhaled biotherapeutic for patients with cystic fibrosis. That therapy aims to break down the problematic mucus in the patient's lungs, while also suppressing dangerous Pseudomonas aeruginosa bacteria.
Vedanta Biosciences is a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria.
Alveolus develops therapeutics for lung diseases such as live biotherapeutics for Bronchopulmonary Dysplasia (BPD), Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), and Pulmonary Arterial Hypertension (PAH).
Seres Therapeutics is a clinical-stage therapeutics company developing products to treat a host of disease conditions based on scientific findings related to the human microbiome. The company is developing candidates for the treatment of infectious, metabolic, and inflammatory diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.